Fennec Pharmaceuticals (FENC) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $16.00 from $13.00 | Aug 12, 2026 |
| B. Riley Securities | Maintained | Buy | $18.00 from $16.00 | Aug 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 from $13.00 | May 22, 2026 |
| Wedbush | Maintained | Outperform | $13.00 | Apr 16, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $18.00 | Jan 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 | Aug 21, 2025 |
| Craig-Hallum | Maintained | Buy | $14.00 from $13.00 | Aug 15, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 | May 20, 2025 |
| Craig-Hallum | Maintained | Buy | $13.00 from $12.00 | May 14, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 | Mar 11, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 | Dec 17, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $15.00 | Aug 22, 2024 |
| Craig-Hallum | Maintained | Buy | $15.00 from $17.00 | Aug 14, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $18.00 | May 15, 2024 |
| Craig-Hallum | Maintained | Buy | $17.00 from $20.00 | May 15, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $17.00 | Apr 4, 2024 |
| Craig-Hallum | Maintained | Buy | $18.00 from $17.00 | Mar 18, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $17.00 from $18.00 | Aug 4, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 | Jun 21, 2023 |
| Cantor Fitzgerald | Maintained | Overweight | $16.00 from $12.00 | Apr 6, 2023 |
Frequently asked questions
Is FENC a buy, sell, or hold?
Analysts covering Fennec Pharmaceuticals currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on FENC?
On Aug 12, 2026, Wedbush maintained Fennec Pharmaceuticals at Outperform with a price target of $16.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.